PE-22-28 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

PE-22-28

Also known as: PE 22-28, spadin analog (7 amino-acid)

Endogenous peptide analog / TREK-1 channel inhibitor

Research chemicalLast updated: October 19, 2026Based on 1 peer-reviewed studyPreclinical data only — no human trials

What it is

PE-22-28 is a small peptide studied in animal models for its antidepressant effects, working by blocking a potassium channel in the brain that influences mood and neurogenesis. It is more potent than related compounds in early lab tests. No FDA-approved use; evidence comes from animal models only.

The scientific side

PE-22-28 is a 7 amino-acid peptide derived from the study of blood degradation products of spadin (PE 12-28). It specifically inhibits the TREK-1 potassium channel with an IC50 of 0.12 nM (versus 40–60 nM for spadin), as demonstrated in hTREK-1/HEK cells using patch-clamp technique. By blocking TREK-1, PE-22-28 exerts antidepressant-like effects, promotes neurogenesis, and enhances synaptogenesis (measured by increased PSD-95 expression) in mouse cortical neurons. Its action duration is up to 23 hours, compared to 7 hours for spadin.

Class: Endogenous peptide analog / TREK-1 channel inhibitor

Administration & storage

Administration
Route of administration not explicitly stated in the reviewed abstract (PMID: 28955242)
Storage
No storage conditions for PE-22-28 are described in the reviewed abstract.
Cautions
No human pharmacokinetic or safety data are available in the reviewed literature — clinical safety profile is unknown.,PE-22-28 is a research-stage peptide; its tolerability, toxicity, and adverse effect profile in humans have not been described in the reviewed abstract.,Modifications to the N- or C-terminal ends of PE-22-28 can abolish TREK-1 channel activity, suggesting that peptide purity and structural integrity are critical.,Sterile technique is essential for any injectable research compound to prevent contamination.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification